Carey Olsen Advised Inflexion On £2.3 Billion Continuation Fund

Carey Olsen Advised Inflexion on £2.3 Billion Continuation Fund

Carey Olsen has advised Inflexion Private Equity Partners LLP on the final close of Inflexion Continuation Fund I at £2.3 billion, marking the largest multi-asset continuation vehicle raised in Europe to date.

The Fund will support four Inflexion portfolio companies – Aspen Pumps, Rosemont Pharmaceuticals, Ocorian, and CNX Therapeutics – in accelerating their growth, particularly through mergers and acquisitions. The transaction will deliver net proceeds of £1.5 billion to existing Inflexion investors, along with a realised return of 3.4x and an internal rate of return (IRR) of 28%. Investors will also have the opportunity to reinvest in the fund. Since its founding in 1999, Inflexion has completed 71 exits, achieving an average realised return of 3.4x and an IRR of 33%.

The Carey Olsen Guernsey corporate team advising on the transaction comprised Andrew Boyce (Partner), Rachel de la Haye (Partner), Oliver Orton (Senior Associate), and Nicola D'Amico (Associate).

Andrew Boyce said "As a long-standing client of Carey Olsen, we are pleased to have supported Inflexion on the successful close of its first continuation fund. This is a significant milestone for Inflexion, which aligns with the firm's strategic focus on organic growth, international expansion and M&A. We look forward to seeing how the fund facilitates the growth of its portfolio companies with the support of investors."

Click to know more about Carey Olsen

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.